Heron Therapeutics Inc to Post FY2022 Earnings of $4.53 Per Share, Leerink Swann Forecasts (HRTX)

Heron Therapeutics Inc (NASDAQ:HRTX) – Equities researchers at Leerink Swann issued their FY2022 EPS estimates for Heron Therapeutics in a research note issued on Tuesday. Leerink Swann analyst A. Fadia forecasts that the biotechnology company will post earnings of $4.53 per share for the year. Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million.

Several other analysts have also recently commented on the stock. Mizuho reiterated a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a research report on Tuesday, November 7th. Cowen reiterated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Monday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 target price on shares of Heron Therapeutics in a research report on Thursday, November 2nd. Oppenheimer started coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They set a “buy” rating and a $27.00 target price for the company. Finally, Noble Financial reiterated a “buy” rating and set a $24.00 target price on shares of Heron Therapeutics in a research report on Friday, October 6th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.82.

Heron Therapeutics (NASDAQ:HRTX) remained flat at $$18.55 during mid-day trading on Thursday. The company had a trading volume of 594,436 shares, compared to its average volume of 1,100,000. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $19.55. The stock has a market cap of $1,010.00, a P/E ratio of -4.89 and a beta of 2.12.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in shares of Heron Therapeutics by 2.2% in the 3rd quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock valued at $93,145,000 after buying an additional 126,039 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Heron Therapeutics by 11.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after buying an additional 221,362 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Heron Therapeutics by 11.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after buying an additional 200,000 shares in the last quarter. Balyasny Asset Management LLC increased its position in shares of Heron Therapeutics by 2.1% in the 2nd quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock valued at $16,916,000 after buying an additional 24,688 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of Heron Therapeutics by 9.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock valued at $12,188,000 after buying an additional 65,260 shares in the last quarter. Institutional investors and hedge funds own 98.78% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Heron Therapeutics Inc to Post FY2022 Earnings of $4.53 Per Share, Leerink Swann Forecasts (HRTX)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/05/heron-therapeutics-inc-to-post-fy2022-earnings-of-4-53-per-share-leerink-swann-forecasts-hrtx.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply